What is MapLight?
MapLight Therapeutics operates at the intersection of neuroscience and advanced drug discovery. Founded by preeminent experts in psychiatry and neuroscience, the company is dedicated to identifying neural circuits that are causally linked to disease. Unlike traditional approaches that may offer broad-spectrum treatments, MapLight’s proprietary platform focuses on the precise modulation of these circuits, offering a more targeted and effective therapeutic paradigm. This focus on circuit-specific medicine positions the company as a high-value innovator within the global biopharmaceutical landscape, particularly as the demand for precision neurology continues to rise among aging populations and those with chronic mental health challenges.
How much funding has MapLight raised?
MapLight has raised a total of $1B across 4 funding rounds:
Series C
$225M
Multiple Rounds
$819.6M
Series C (2023): $225M with participation from 5AM Ventures, Cowen Healthcare Investments, and Novo Holdings
Stock/Share Issuance (2025): $188.2M, investors not publicly disclosed
Series D (2025): $372.5M supported by T. Rowe Price, Avego, Sanofi, Forbion, and Goldman Sachs Asset Management
Stock/Share Issuance (2025): $258.9M, investors not publicly disclosed
Key Investors in MapLight
T. Rowe Price
T. Rowe Price is a global asset management organization providing investment solutions and financial services to individuals, institutions, and retirement plan sponsors through active management and fundamental research.
Avego
Avego is a multi-strategy investment firm dedicated to the healthcare sector, providing growth capital to private and public companies to enhance patient outcomes.
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation, focusing on medicines and vaccines across immunology, neurology, and oncology.
What's next for MapLight?
With the recent influx of capital, MapLight Therapeutics is well-positioned to scale its clinical operations and deepen its research capabilities. The strategic focus will likely shift toward advancing its lead candidates through late-stage clinical trials while simultaneously expanding its discovery platform to identify new therapeutic targets. As the company navigates the complexities of drug development, the continued support from its diverse investor base—ranging from global asset managers to specialized life science venture firms—provides the operational stability required to navigate regulatory hurdles and bring transformative medicines to market. The firm’s ability to maintain this momentum will be critical in establishing its long-term dominance in the CNS therapeutic space.
See full MapLight company page
